GeneThera, Inc. - 2009 a Year for Opportunity and Growth - An Update to Shareholders

WHEAT RIDGE, CO--(Marketwire - December 30, 2008) - GeneThera, Inc. (PINKSHEETS: GTHR), as a service and responsibility to our shareholders, is publicly outlining our strategy for the future of the company.

In recent announcements, we have outlined some major directional changes for the company. We have committed to becoming a revenue generating entity, we have committed to bringing our E.Coli vaccine to market, and we have committed to continue development of our Johne’s disease vaccine. Now we are adding further commitments. With the incoming change of governmental administration, and the recent developments with Mexico refusing to accept meat from US meat packers, we are announcing that we will resume development of our Live Animal BSE Assay.

RECENT DEVELOPMENTS

Mexico Johne’s Validation Trials - We have received contractual documents from UNAM (Mexican Federal University) to begin validation of our real time PCR Johne’s disease test for use in Mexico. We are expecting to finalize the contract and begin the set up of our laboratory there within 90 days.

United States commercialization of Johne’s test - We are in discussions with a major animal health and veterinary distributor to become the US marketing and distribution arm for the service. We have finalized the laboratory system utilizing Roche Diagnostics equipment, and expect to have the lab operational within 45 days. We are able to perform limited number of tests with our current laboratory system.

E.Coli Vaccine - We have several large animal health pharmaceutical companies currently reviewing the technology for potential partnership. We are also pleased to say we are having dialogue with some of the large produce grower organizations. We feel that with enough pressure, the Obama administration will be forced to create legislation requiring vaccinating of all cattle to prevent harmful E.Coli contaminations.

2009 Goals

*Approval of Johne’s disease test in Mexico, and subsequent commercialization of the test to ranchers.

*Meet our forecasted goals for revenue based on US Johne’s disease testing service.

*Perform initial animal trials for Johne’s disease vaccine, and prepare for Pilot trials.

*Perform Pilot trial and begin US clinical trials for E.Coli vaccine.

*Reach validation point for Live Animal BSE (mad cow disease) test.

*Acquire or develop new BSE testing technology to work in conjunction with our own test.

*Grow our Wheat Ridge headquarters staff.

We will be keeping our shareholders updated in the near future with financial forecasts, strategic partnership developments, joint ventures, and any other news that may affect the structure or operations of the company.

In conclusion, we at GeneThera want to once again thank our loyal shareholders for their continued support. We encourage you to contact us for more details on our plans and expectations for the future.

Dr. Antonio Milici, MD PHD

ABOUT GENETHERA, INC.

GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, Colorado. The Company provides genetic diagnostic solutions for the veterinary and agricultural industries with future plans to include the healthcare industry. The Company’s proprietary diagnostic solution is based on a genetic expression assay, GES™, a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GES is designed for a host of individual diseases, the current priorities being Mad Cow disease, Chronic Wasting Disease, E.Coli 0157:H7 and Johne’s disease, all diseases affecting cattle worldwide. For more information, contact Dr. Tony Milici at 303-463-6371 or Al Goldsmith of The Goldsmith Group LLC at 303-838-4370.

This press release contains forward-looking statements, which are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “intends,” “believes,” and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company’s filings with the Securities and Exchange Commission. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.